Neuroendocrine tumors (NETs) of cystic duct are extremely rare, accounting for less than 2% of NET cases. The association of biliary tree NET and multiple endocrine neoplasm type 1 (MEN1) are even more rare. In this report, we described a case of a 65-year-old woman who was referred to our neuroendocrine outpatient clinic to investigate MEN1 after an incidental diagnosis of gastrinoma. Her medical history initiated 7 years earlier with severe peptic disease not responsive to proton pump inhibitor therapy. Endoscopic study revealed erosive antral gastritis, erosive duodenitis, bulbar ulcer and pyloric deformity. During follow-up she presented with abdominal pain, chronic diarrhea and weight loss; an ultrasonography was performed and showed only a cholelithiasis. She underwent a video laparoscopic cholecystectomy and all her symptoms were solved. Histopathological study found a 1.0 cm well differentiated NET (Ki-67 labeling index < 2%) located in cystic duct infiltrating the entire wall and subserosa. The MEN1 investigation revealed a primary hyperparathyroidism with a brown tumor in right iliac bone; the patient was referred to a total parathyroidectomy with autotransplantation. No evidence of pituitary tumor was found. The patient remains asymptomatic 24 months after surgery. To conclude, this case highlights an unusual presentation of a cystic duct primary NET gastrinoma in a MEN1 context.
Introduction
Neuroendocrine tumors (NETs) are neoplasms of variable malignant potential, which arise from the embryonic neural crest cells. The enteropancreatic NET occurs in up to 60% of multiple endocrine neoplasia type1 (MEN1) patients [1] [2] [3] .
Extrahepatic biliary NET is an extremely rare malignancy [4, 5] . They account for 0.2% to 2% of all NET of the gastrointestinal tract; and the most common sites include the common biliary duct (CBD), followed by the perihilar region, cystic duct and common hepatic duct (CHD) [4] [5] [6] . Rarely the extrahepatic biliary tree NETs are gastrinomas, and there are less than 10 cases associated with MEN1 reported in the literature [3, 7, 8] . They commonly occur in young females and the clinical condition is variable; some cases may be diagnosed as incidental finding post-cholecystectomy [4, 5] . In general, surgical approach is recommended [4, 5] .
Our case describes a patient with a cystic duct gastrinoma diagnosed after videolaparoscopic cholecystectomy in a context of MEN1.
Case Report
A 65-year-old female was referred to our neuroendocrine outpatient clinic for a complete assessment of MEN1. Her clinical history began at the age of 58 with mesogastric pain mainly after fatty food intake, chronic diarrhea and steatorrhea and 4.95 kg weight loss in that time period.
The patient had 7 years of severe peptic disease not responsive to proton pump inhibitor (PPI) therapy (omeprazole 80 mg/day) and kidney stones. Her family history consisted of a sister who had a diagnosis of hyperparathyroidism. Her physical examination was normal.
A laboratory evaluation for hepatitis, celiac disease, inflammatory bowel disease and intestinal protozoal infections were performed and no abnormality was found.
Initial abdominal ultrasonography (US) was normal but approximately 1 year later a repeated US showed cholelithiasis and a dilated choledochal duct (0.9 cm). Esophago-gastro-duodenoscopy (EGDS) showed the presence of reflux esophagitis (Los Angeles B), erosive antral gastritis, erosive duodenitis, bulbar ulcer and pyloric deformity (Fig.  1 Neuroendocrine Tumor of Cystic Duct and MEN1 J Clin Med Res. 2018;10(11):843-847
ileum. She underwent a videolaparoscopic cholecystectomy and histopathological examination revealed a well differentiated NET grade 1 (Ki-67 labeling index < 2%) and immunostaining positive for chromogranin A (CgA) and synaptophysin (Syn) (Fig. 2) . The NET was located at the cystic duct, measured 1.0 cm and infiltrated the entire wall and subserosa. Surgical margins of the cystic duct were free, but exiguous.
No presence of angiolymphatic or perineural invasion was detected.
After surgery the patient has no more abdominal pain or peptic symptoms. The clinical diagnosis of gastrinoma with Zollinger-Ellison Syndrome (ZES) was established and MEN1 screening showed elevated levels of calcium and parathyroid hormone (PTH). No abnormality in prolactin and insulin-like growth factor 1 (IGF-1) levels were observed (Table 1). The pituitary gland magnetic resonance imaging (MRI) was normal. Postoperative gastrin and CgA serum levels were normal (Table 1) . During 24 months on regular follow-up the patient has not presented diarrhea and gained 19.8 kg. She remains with no peptic symptoms and no PPI therapy. Abdominal computerized tomography (CT) scan had no abnormality. The EGDS was normal 10 months after surgery (Fig. 3) . Thus, no adjuvant therapy was indicated. During follow-up, an investigation concerning the patient complaint of a right hip pain revealed a brown tumor in the right femoral trochanter. The bone densitometry also revealed osteoporosis. She was referred to a total parathyroidectomy with autotransplantation. At the time of the last follow-up no pituitary disease was detected. Verbal and written informed consent was obtained from the patient for publication in this case report.
Discussion
Gastrinomas are the most common functional enteropancreatic NET and are more frequently localized in the duodenum and less commonly in the pancreas. Approximately 20% of gastrinomas are associated with MEN1 syndrome [9] , and in this context the duodenum is the predominant primary location. Tonelli et al [3] described three patients with MEN1 and ZES presenting with ectopic gastrinomas located in the biliary tree and coexisting duodenal gastrinomas. In two cases the biliary tree gastrinomas were identified during surgery and in one case the diagnosis was made 1 year after the first surgery in a patient with persistent ZES. Another report described a case of a primary hepatic gastrinoma in a patient with MEN1 and ZES [8] . There are two other cases of biliary tree gastrinomas in MEN1 patients and ZES [7] . In our patient a coexisting duodenal gastrinoma could not be found, she remained asymptomatic with normal EGDS and gastrin levels more than 24 months after surgery, also an echo upper endoscopy did not show any submucosal lesion in the duodenum. The patient remains in close follow-up.
To date, we presented the seventh case described in the literature regarding an ectopic gastrinoma in MEN1 patients with ZES. Also, this is the second case to describe a patient with an exclusive biliary tree gastrinoma (duodenum not affected) in a patient with MEN1. Table 2 [3, 7, 8] summarizes all seven cases. Longer follow-up is necessary before we can rule out a small duodenal occult lesion.
We have to be aware of certain signs and symptoms that may lead us to suspect of a gastrinoma such as gastroesophageal reflux symptoms, multiple ulcers, ulcers in unusual locations (post-bulbar regions), diarrhea, steatorrhea, weight loss or necessity to use high doses of PPI to control or treat the symptoms/diseases or the inability to control/treat them de- Neuroendocrine Tumor of Cystic Duct and MEN1 J Clin Med Res. 2018;10(11):843-847 Two out of 31 lymph nodes examined had neuroendocrine tumor tissue positive for gastrin after surgery including the removal of the regional lymph nodes.
NA: not available.
Moraes et al J Clin Med Res. 2018;10(11):843-847 spite high doses of PPI. And whenever faced with a patient with hyperparathyroidism and suggestive clinical features of gastrinoma we have to look for MEN1 syndrome. Although ZES has not been suspected before surgery even in the presence of peptic symptoms, it was possible after surgery.
In the context of ZES in MEN1 patients we must also be aware of extraduodenal primaries mainly during surgical procedures where we need to inspect the biliary tree. An occult extra duodenal gastrinoma may be the cause of surgery failure after duodenopancreatectomy, mainly in cases of ZES symptoms persistence.
Based on these results, we concluded that the patient had a primary NET of cystic duct, a gastrinoma and a primary hyperparathyroidism that may co-exist in patients with MEN1.
